Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Roivant Sciences Ltd (NQ: ROIV ) 11.57 -0.20 (-1.70%) Streaming Delayed Price Updated: 4:00 PM EDT, Sep 26, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Roivant Sciences Ltd < Previous 1 2 3 4 5 6 7 Next > 2 Nasdaq Stocks That Could Soar This Week July 16, 2023 BridgeBio Pharma and Roivant Sciences could make big moves this week. Via The Motley Fool Hollywood Wants To Use AI Replicas Of Actors, Major US Banks Deliver Q2 Earnings, Artificial Sweetener Aspartame Classified As 'Possible Carcinogen:' Today's Top Stories July 14, 2023 Benzinga Via Benzinga Roivant Surges As Roche Reportedly Considers $7 Billion Drug Takeover July 14, 2023 The report sent Roivant Sciences higher Friday, but a deal is far from guaranteed. Via Investor's Business Daily Republican Presidential Candidate Vivek Ramaswamy Founded Roivant In Discussions With Roche For $7B Stomach Disease(s) Drug Deal July 14, 2023 Roivant Sciences Ltd (NASDAQ: ROIV), a biotech company founded by Vivek Ramaswamy, a Republican presidential candidate, is reportedly in discussions with Roche Holdings AG (OTC: RHHBY) Via Benzinga Roivant Sciences's Return on Invested Capital Insights June 29, 2023 Via Benzinga Analyst Expectations for Roivant Sciences's Future June 29, 2023 Via Benzinga Why Shares of Roivant Sciences Rose Wednesday June 28, 2023 The pharmaceutical company released fourth-quarter earnings. Via The Motley Fool Why Roivant Sciences Stock is Trading Higher Today June 22, 2023 Roivant Sciences Ltd (NASDAQ: ROIV) released results from the chronic period of the TUSCANY-2 Phase 2b study of RVT-3101 in adult patients with Via Benzinga Roivant Ranks No. 25 on Fast Company’s Fifth Annual List of the 100 Best Workplaces for Innovators and is the Winner on the Science and Technology List as a Part of the Best Workplaces for Innovators Program July 11, 2023 Joining Adobe, Spotify, Nvidia, Morgan Stanley, and many others From Roivant Sciences Via GlobeNewswire Schrödinger To Rally Around 14%? Here Are 10 Other Analyst Forecasts For Thursday June 29, 2023 Keybanc boosted the price target for Micron Technology, Inc. (NASDAQ: MU) from $70 to $80. Keybanc analyst John Vinh maintained an Overweight rating. Micron shares rose 3.9% to $69.70 in pre-market... Via Benzinga UPDATE -- Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2023, and Provides Business Update June 28, 2023 From Roivant Sciences Via GlobeNewswire A First-Ever In Ulcerative Colitis Sends Roivant Stock Into A Breakout June 22, 2023 The company is testing a treatment that blocks an inflammatory ligand in patients with ulcerative colitis. Via Investor's Business Daily 5 Analysts Have This to Say About Roivant Sciences June 08, 2023 Via Benzinga Why Shares of Roivant Sciences Jumped This Week April 20, 2023 The company's stock benefited from another company's buyout. Via The Motley Fool Nasdaq, S&P 500 Futures Slip Ahead Of Powell Speech, Bank Stress Test Results: Why This Analyst Rates Stocks 'Overweight' And Says 'Buy Weakness' June 28, 2023 Via Benzinga Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2023, and Provides Business Update June 28, 2023 From Roivant Sciences Via GlobeNewswire Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2023, and Provide Business Update on Wednesday, June 28, 2023 June 26, 2023 From Roivant Sciences Via GlobeNewswire Why Avid Bioservices Shares Are Trading Lower By Over 14%? Here Are Other Stocks Moving In Thursday's Mid-Day Session June 22, 2023 Gainers Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE) shares climbed 422% to $0.5572 after the company announced acquisition of Spyre Therapeutics and concurrent oversubscribed $210 million private... Via Benzinga Why Roivant Sciences Stock Is Perking Up Today June 22, 2023 Positive long-term data for a novel ulcerative colitis medication is fueling a double-digit rise in the drugmaker's stock. Via The Motley Fool Steelcase, Commercial Metals And Other Big Stocks Moving Higher On Thursday June 22, 2023 U.S. stocks traded mixed, with the Dow Jones dropping around 50 points on Thursday. Here are some big stocks recording gains in today’s session. Via Benzinga Roivant Reports Chronic Period Data for RVT-3101 from the TUSCANY-2 Phase 2b Study in Ulcerative Colitis, Demonstrating Improved Efficacy from the Induction to Chronic Period June 22, 2023 From Roivant Sciences Via GlobeNewswire Roivant to Host Investor Call at 8:00 AM ET on Thursday, June 22 to Review Results from the Chronic Period of TUSCANY-2, a Large Global Phase 2b Study of RVT-3101 (Anti-TL1A Antibody) in Ulcerative Colitis June 21, 2023 From Roivant Sciences Via GlobeNewswire Benzinga's Top Ratings Upgrades, Downgrades For June 8, 2023 June 08, 2023 Via Benzinga The Biotech Buying Bonanza: Why The FTC's Amgen Battle Won't Chill The Spree June 02, 2023 Big Pharma is facing a patent cliff that could siphon off billions in revenue. Via Investor's Business Daily Marching Towards FDA Approval: Dermavant's Vtama Cream Excels in Phase 3 Trial, Eyes 2024 Submission May 16, 2023 Dermavant Sciences, a Roivant Sciences (NASDAQ: ROIV) company, announced results from ADORING 1 Phase 3 trial of topical Vtama (tapinarof) cream, 1% in adults and pediatric subjects down to 2 years old... Via Benzinga Roivant Reports Positive Topline Results from ADORING 1, the Second Atopic Dermatitis Phase 3 Trial of VTAMA® (tapinarof) Cream, 1% in Adults and Children as Young as 2 Years Old May 16, 2023 From Roivant Sciences Via GlobeNewswire Why Did Pfizer Offload This Potential Mega-Blockbuster Drug? April 23, 2023 Pfizer's decision to offload a potential mega-blockbuster may seem counterintuitive, but the drugmaker appears to have solid reasons for doing so. Via The Motley Fool These 2 Growth Stocks Might Be Incredibly Undervalued Right Now April 20, 2023 These two biopharma stocks could be poised for a major growth spurt. Via The Motley Fool EXCLUSIVE: Joe Biden Tops 2024 Election Betting Odds, How Negative Headlines And Indictment Move Trump Ahead Of DeSantis April 17, 2023 While the 2024 U.S. presidential election may seem a long way off, polls to see who is favored by voters and betting odds for the next White House occupant have ramped up. Via Benzinga These 3 Nasdaq Stocks Are on Fire Today: Here's Why April 17, 2023 A high-dollar buyout is lighting a fire underneath these three Nasdaq stocks today. Via The Motley Fool < Previous 1 2 3 4 5 6 7 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.